scholarly journals Experimentally Induced Mammalian Models of Glaucoma

2015 ◽  
Vol 2015 ◽  
pp. 1-11 ◽  
Author(s):  
Makoto Ishikawa ◽  
Takeshi Yoshitomi ◽  
Charles F. Zorumski ◽  
Yukitoshi Izumi
Keyword(s):  
Animal Models ◽  
Disease Progression ◽  
Review Paper ◽  
Therapeutic Strategies ◽  
Ideal Model ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic ◽  
Experimentally Induced

A wide variety of animal models have been used to study glaucoma. Although these models provide valuable information about the disease, there is still no ideal model for studying glaucoma due to its complex pathogenesis. Animal models for glaucoma are pivotal for clarifying glaucoma etiology and for developing novel therapeutic strategies to halt disease progression. In this review paper, we summarize some of the major findings obtained in various glaucoma models and examine the strengths and limitations of these models.

scholarly journals Feasibility of large experimental animal models in testing novel therapeutic strategies for diabetes

2021 ◽  
Vol 12 (4) ◽  
pp. 306-330
Author(s):  
Masaki Nagaya ◽  
Koki Hasegawa ◽  
Ayuko Uchikura ◽  
Kazuaki Nakano ◽  
Masahito Watanabe ◽  
...  
Keyword(s):  
Animal Models ◽  
Experimental Animal ◽  
Therapeutic Strategies ◽  
Experimental Animal Models ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

scholarly journals Animal Models of Drug Addiction in Support of Novel Therapeutic Strategies

ILAR Journal ◽  
2011 ◽  
Vol 52 (3) ◽  
pp. 233-238 ◽  
Author(s):  
J. Frascella ◽  
K. A. Richardson ◽  
G. L. McLemore
Keyword(s):  
Animal Models ◽  
Drug Addiction ◽  
Therapeutic Strategies ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies

2012 ◽  
Vol 61 (1) ◽  
pp. 25-41 ◽  
Author(s):  
Sameer Agnihotri ◽  
Kelly E. Burrell ◽  
Amparo Wolf ◽  
Sharzhad Jalali ◽  
Cynthia Hawkins ◽  
...  
Keyword(s):  
Animal Models ◽  
Molecular Genetics ◽  
Therapeutic Strategies ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol

2018 ◽  
Vol 19 (2) ◽  
pp. 165-176 ◽  
Author(s):  
Yan Wang ◽  
Zhao-Peng Liu
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Maximum Tolerated Dose ◽  
Therapeutic Strategies ◽  
Low Density ◽  
Pcsk9 Inhibitors ◽  
Cvd Risk ◽  
Safety Issues ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

Statins are currently the major therapeutic strategies to lower low-density lipoprotein cholesterol (LDL-C) levels. However, a number of hypercholesterolemia patients still have a residual cardiovascular disease (CVD) risk despite taking the maximum-tolerated dose of statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low-density lipoprotein receptor (LDLR), inducing its degradation in the lysosome and inhibiting LDLR recirculating to the cell membranes. The gain-offunction mutations in PCSK9 elevate the LDL-C levels in plasma. Therefore, PCSK9 inhibitors become novel therapeutic approaches in the treatment of hypercholesterolemia. Several PCSK9 inhibitors have been under investigation, and much progress has been made in clinical trials, especially for monoclonal antibodies (MoAbs). Two MoAbs, evolocumab and alirocumab, are now in clinical use. In this review, we summarize the development of PCSK9 inhibitors, including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), small molecule inhibitor, MoAbs, mimetic peptides and adnectins, and the related safety issues.

scholarly journals The Senescence-Associated Secretory Phenotype (SASP) in the Challenging Future of Cancer Therapy and Age-Related Diseases

Biology ◽  
2020 ◽  
Vol 9 (12) ◽  
pp. 485
Author(s):  
Lorenzo Cuollo ◽  
Fabrizio Antonangeli ◽  
Angela Santoni ◽  
Alessandra Soriani
Keyword(s):  
Cancer Therapy ◽  
Molecular Mechanisms ◽  
Therapeutic Strategies ◽  
Senescent Cell ◽  
Pharmacological Intervention ◽  
Tissue Microenvironment ◽  
Age Related ◽  
Secretory Phenotype ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

Cellular senescence represents a robust tumor-protecting mechanism that halts the proliferation of stressed or premalignant cells. However, this state of stable proliferative arrest is accompanied by the Senescence-Associated Secretory Phenotype (SASP), which entails the copious secretion of proinflammatory signals in the tissue microenvironment and contributes to age-related conditions, including, paradoxically, cancer. Novel therapeutic strategies aim at eliminating senescent cells with the use of senolytics or abolishing the SASP without killing the senescent cell with the use of the so-called “senomorphics”. In addition, recent works demonstrate the possibility of modifying the composition of the secretome by genetic or pharmacological intervention. The purpose is not to renounce the potent immunostimulatory nature of SASP, but rather learning to modulate it for combating cancer and other age-related diseases. This review describes the main molecular mechanisms regulating the SASP and reports the evidence of the feasibility of abrogating or modulating the SASP, discussing the possible implications of both strategies.

Sign in / Sign up

Export Citation Format

Share Document